Rchr
J-GLOBAL ID:200901070561721820   Update date: Apr. 23, 2024

Murayama Takashi

ムラヤマ タカシ | Murayama Takashi
Affiliation and department:
Job title: Associate Professor
Homepage URL  (1): http://pharmacology.sakura.ne.jp/jp/staff.html#murayama
Research field  (3): Clinical pharmacy ,  Physiology ,  Pharmacology
Research keywords  (2): 薬理学 ,  Pharmacology
Research theme for competitive and other funds  (23):
  • 2022 - 2025 筋肉熱シグナリング破綻・暴走の個体解析
  • 2022 - 2025 Elucidation of molecular mechanism for depolarization-induced Ca2+ release using novel reconstitution system
  • 2021 - 2024 Structural analysis of the gating mechanism of cardiac ryanodine receptor
  • 2021 - 2024 The construction of exercise therapy in familial DCM model mice
  • 2019 - 2022 新規リアノジン受容体作用薬を利用したサブタイプ特異的チャネル制御の分子機構
Show all
Papers (120):
  • Yuta Okabe, Nobuyuki Murakoshi, Nagomi Kurebayashi, Hana Inoue, Yoko Ito, Takashi Murayama, Chika Miyoshi, Hiromasa Funato, Koichiro Ishii, Dongzhu Xu, et al. An inherited life-threatening arrhythmia model established by screening randomly mutagenized mice. Proceedings of the National Academy of Sciences of the United States of America. 2024. 121. 17. e2218204121
  • Mai Takenaka, Masami Kodama, Takashi Murayama, Mari Ishigami-Yuasa, Shuichi Mori, Ryosuke Ishida, Junji Suzuki, Kazunori Kanemaru, Masami Sugihara, Masamitsu Iino, et al. Screening for Novel Type 2 Ryanodine Receptor Inhibitors by Endoplasmic Reticulum Ca2+ Monitoring. Molecular pharmacology. 2023. 104. 6. 275-286
  • Jianshu Hu, Elisa Venturi, Charalampos Sigalas, Takashi Murayama, Miyuki Nishi, Hiroshi Takeshima, Rebecca Sitsapesan. The biophysical properties of TRIC-A and TRIC-B and their interactions with RyR2. Journal of General Physiology. 2023
  • Ryosuke Ishida, Nagomi Kurebayashi, Hiroto Iinuma, Xi Zeng, Shuichi Mori, Masami Kodama, Takashi Murayama, Hiroyuki Masuno, Fumi Takeda, Masatoshi Kawahata, et al. A potent and selective cis-amide inhibitor of ryanodine receptor 2 as a candidate for cardiac arrhythmia treatment. European journal of medicinal chemistry. 2023. 262. 115910-115910
  • Takashi Murayama, Nagomi Kurebayashi, Ryosuke Ishida, Hiroyuki Kagechika. Drug development for the treatment of RyR1-related skeletal muscle diseases. Current opinion in pharmacology. 2023. 69. 102356-102356
more...
MISC (169):
more...
Patents (1):
Books (2):
  • Ryanodine Receptor(共著)
    続心臓代謝実験法 1998
  • Further characterozation of ryanodine receptor isoforms purified from bullfrog skeletal muscle(共著)
    Calcium as Cell Signal (K.Maruyama,Y.Nonomura,and K.Kohama eds.),lgaku Shoin Ltd.,Tokyo 1995
Education (4):
  • 1988 - 1990 千葉大学大学院 理学研究科 生物学専攻
  • - 1990 Chiba University Graduate School, Division of Natural Science
  • 1984 - 1988 Chiba University Faculty of Science Department of Biology
  • - 1988 Chiba University Faculty of Science
Professional career (2):
  • Doctor of Philosophy (Juntendo University)
  • Master of Biology (Chiba University)
Work history (4):
  • 2022/02 - 現在 Juntendo University Faculty of Medicine
  • 2007/04 - 2022/01 Juntendo University Faculty of Medicine
  • 1997/04 - 2007/03 Juntendo University Faculty of Medicine
  • 1990/04 - 1997/03 Juntendo University Faculty of Medicine
Association Membership(s) (11):
JAPANESE SOCIETY OF ANESTHESIOLOGISTS ,  日本生理学会 ,  American Physiological Society ,  Biophysical Society ,  日本薬理学会 ,  American Physiological Society ,  Biophysical Society ,  The Biophysical Society of Japan ,  Physiological Society of Japan ,  The Japanese Biochemical Society ,  The Japanese Pharmacological Society
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page